Discovery & Clinical Trials
News and Publications
Discovering, developing & commercializing broad-spectrum antivirals
Dedicated to preventing and treating life- threatening viral infections
Innovation to address high unmet medical needs
Welcome to Chimerix
(NASDAQ: CMRX) Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need.
SUPPRESS Phase 3 Trial
SUPPRESS is designed to demonstrate the efficacy and safety of brincidofovir for the prevention of CMV infection versus a placebo control, as no therapy is currently approved for the prevention of CMV in HCT recipients.
Jul 23 2015
Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
Jun 18 2015
Chimerix to Present at the JMP Life Sciences Conference
Jun 16 2015
Chimerix Announces Exercise in Full of Option to Purchase Additional Shares of Common Stock